Oragenics (OGEN) Liabilities from Discontinued Operations (2015 - 2016)
Oragenics' (OGEN) quarterly Liabilities from Discontinued Operations came in at 11394.0 in Q3 2016, down 93.28% on a QoQ basis from 169479.0 in Q2 2016.
Oragenics (OGEN) Liabilities from Discontinued Operations (2015 - 2016) Analysis & Trends
Oragenics (OGEN) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 11394.0 in Q3 2016.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 11394.0 in Q3 2016, while the trailing twelve-month figure through Sep 2016 was 11394.0 (changed N/A YoY) and the FY2015 annual result came in at 152973.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations eased to 11394.0 in Q3 2016, from 169479.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 169479.0 in Q2 2016 to a low of 11394.0 in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Oragenics | 2.31 Mn | 2.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 11,394.00 |
| Sep 30, 2016 | 11,394.00 |
| Jun 30, 2016 | 169,479.00 |
| Jun 30, 2016 | 169,479.00 |
| Dec 31, 2015 | 152,973.00 |
| Dec 31, 2015 | 152,973.00 |